Securities code: 600252 securities abbreviation: Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) Announcement No.: pro 2022-3 Guangxi Wuzhou Zhongheng Group Co.Ltd(600252)
Announcement of annual performance reduction in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. Important content tips:
1. Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) (hereinafter referred to as "the company" or " Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) ") the net profit attributable to shareholders of Listed Companies in 2021 is expected to decrease by 168.8199 million yuan to 28.18199 million yuan, a year-on-year decrease of 30% to 50% compared with the same period of the previous year (statutory disclosure data).
2. Compared with the same period of the previous year (legally disclosed data), the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses is expected to decrease by 217.4697 million yuan to 330.4697 million yuan, a year-on-year decrease of 49% to 74%. 1、 Performance forecast of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
1. According to the preliminary calculation of the financial department, the net profit attributable to the shareholders of the listed company in 2021 is expected to be reduced by 168.8199 million yuan to 28.18199 million yuan, a year-on-year decrease of 30% to 50% compared with the same period of the previous year (statutory disclosure data).
2. Compared with the same period of the previous year (legally disclosed data), the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses is expected to decrease by 217.4697 million yuan to 330.4697 million yuan, a year-on-year decrease of 49% to 74%. (III) the relevant financial data of this performance forecast have not been audited by certified public accountants.
2、 Performance in the same period of last year
(I) net profit attributable to shareholders of listed companies: 562.82 million yuan; Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses: 446469800 yuan.
(II) earnings per share: 0.1643 yuan.
3、 Main reasons for performance reduction in the current period
The performance reduction is mainly due to the impact of main business. First, affected by covid-19 epidemic. The epidemic situation has been repeated all over the country, the number of hospitalizations in medical institutions and hospitals in some regions has decreased, and the amount of prescription drugs has decreased; Pharmacies are restricted to the sale of antipyretic and antitussive drugs, and the company's related OTC varieties are restricted to the sale. Second, the main product Xueshuantong is affected by the cross provincial joint centralized procurement policies of Hubei and Guangdong, and the medical institutions and indications are limited, resulting in the slow progress of product sales. Third, the main product of the company's holding subsidiary Chongqing Lummy Pharmaceutical Co.Ltd(300006) (hereinafter referred to as " Chongqing Lummy Pharmaceutical Co.Ltd(300006) ") lemeisu products failed to enter the list of volume procurement by the National Medical Insurance Bureau, and the income decreased to a certain extent. Fourth, the performance of Chongqing Lummy Pharmaceutical Co.Ltd(300006) did not meet the expectations at the time of M & A. It is estimated that the impairment of goodwill in 2021 will be between 150 million yuan and 250 million yuan.
4、 Risk tips
The company has not found any major uncertain factors affecting the accuracy of the performance forecast.
5、 Other explanatory matters
The above forecast data are only preliminary accounting data. The specific and accurate financial data are subject to the audited annual report of 2021 officially disclosed by the company. Please pay attention to the investment risks.
It is hereby announced.
Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) board of directors January 26, 2022
